As the world becomes increasingly uncertain, Core Laboratories N.V. (CLB) offers stability

Core Laboratories N.V. (NYSE: CLB) closed the day trading at $20.21 down -0.39% from the previous closing price of $20.29. In other words, the price has decreased by -$0.08 from its previous closing price. On the day, 723295 shares were traded. CLB stock price reached its highest trading level at $20.64 during the session, while it also had its lowest trading level at $19.56.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



For a better understanding of CLB, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 63.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 75.72. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 2.10. In the meantime, Its Debt-to-Equity ratio is 0.94 whereas as Long-Term Debt/Eq ratio is at 0.94.

Upgrades & Downgrades

On October 07, 2022, Citigroup Upgraded its rating to Neutral which previously was Sell and also lowered its target price recommendation from $24 to $17.

Morgan Stanley Downgraded its Equal-Weight to Underweight on September 26, 2022, while the target price for the stock was maintained at $20.

Valuation Measures:

As of this moment, Core’s Price-to-Earnings (P/E) ratio for their current fiscal year is 48.70, and their Forward P/E ratio for the next fiscal year is 15.63. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.39. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.99 while its Price-to-Book (P/B) ratio in mrq is 5.09.

Stock Price History:

Over the past 52 weeks, CLB has reached a high of $34.08, while it has fallen to a 52-week low of $13.19. The 50-Day Moving Average of the stock is 23.98, while the 200-Day Moving Average is calculated to be 20.28.

Shares Statistics:

Over the past 3-months, CLB traded about 352.61K shares per day on average, while over the past 10 days, CLB traded about 419.62k shares per day. A total of 46.38M shares are outstanding, with a floating share count of 46.13M. Shares short for CLB as of Jan 30, 2023 were 3.75M with a Short Ratio of 3.69M, compared to 3.61M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 8.08% and a Short% of Float of 13.36%.

Dividends & Splits

CLB’s forward annual dividend rate is 0.04, up from 0.04 a year ago. Against a Trailing Annual Dividend Yield of 0.20%, it implies a Forward Annual Dividend Yield of 0.16%. The stock’s 5-year Average Dividend Yield is 2.54. The current Payout Ratio is 9.50% for CLB, which recently paid a dividend on Mar 05, 2023 with an ex-dividend date of Feb 09, 2023. Stock splits for the company last occurred on Jul 08, 2010 when the company split stock in a 2:1 ratio.

Earnings Estimates

Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $0.17 for the current quarter, with a high estimate of $0.19 and a low estimate of $0.16, while EPS last year was $0.08. The consensus estimate for the next quarter is $0.22, with high estimates of $0.24 and low estimates of $0.21.

Analysts are recommending an EPS of between $1.07 and $0.85 for the fiscal current year, implying an average EPS of $1. EPS for the following year is $1.37, with 7 analysts recommending between $1.59 and $1.14.

Revenue Estimates

3 analysts predict $127.72M in revenue for the current quarter. It ranges from a high estimate of $129.1M to a low estimate of $127M. As of the current estimate, Core Laboratories N.V.’s year-ago sales were $115.3M, an estimated increase of 10.80% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $133.78M, an increase of 10.70% less than the figure of $10.80% in the same quarter last year. There is a high estimate of $134.65M for the next quarter, whereas the lowest estimate is $133M.

A total of 6 analysts have provided revenue estimates for CLB’s current fiscal year. The highest revenue estimate was $564.34M, while the lowest revenue estimate was $542M, resulting in an average revenue estimate of $550.24M. In the same quarter a year ago, actual revenue was $489.74M, up 12.40% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $606.37M in the next fiscal year. The high estimate is $618.56M and the low estimate is $596.5M. The average revenue growth estimate for next year is up 10.20% from the average revenue estimate for this year.